NCT01003418View on ClinicalTrials.gov

Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 17, 2009

Primary Completion Date

November 25, 2010

Study Completion Date

November 25, 2010

Conditions
Influenza
Interventions
BIOLOGICAL

GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine

Two doses; intramuscular administration

BIOLOGICAL

Infanrix™-IPV/Hib

Routine infant immunisation vaccine, three doses administered intramuscularly

BIOLOGICAL

Prevenar

Routine infant immunisation vaccine, three doses administered intramuscularly

Trial Locations (4)

3420

GSK Investigational Site, Lierskogen

5021

GSK Investigational Site, Bergen

N-3515

GSK Investigational Site, Hønefoss

0027

GSK Investigational Site, Oslo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01003418 - Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children | Biotech Hunter | Biotech Hunter